Vismodegib
CAS No. : 879085-55-9
(Synonyms: GDC-0449)
| Size | Price | Stock |
|---|---|---|
| 10mg | $66 | In-stock |
| 50mg | $86 | In-stock |
| 100mg | $111 | In-stock |
| 200mg | $145 | In-stock |
| 500 mg | Get quote | |
| 1 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-10440 |
| M.Wt: | 421.30 |
| Formula: | C19H14Cl2N2O3S |
| Purity: | >98 % |
| Solubility: | DMSO : 50 mg/mL (ultrasonic);Ethanol : 3.33 mg/mL (ultrasonic;warming;heat to 60°C) |
Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively[1][2]. IC50 & Target: IC50: 3 nM (hedgehog), 3.0 μM (P-gp), 1.4 μM (ABCG2)[1][2] In Vitro: Vismodegib (HhAntag691) is an ABCG2 inhibitor and can increase the effective intracellular concentration of NSC 279836, another ABCG2 substrate, through blocking its export in HEK293 cells. Vismodegib (HhAntag691, 10 µM), resensitizes MDCKII/Pgp cells and MDCKII/MRP1 cells to NSC757 treatment[2]. Vismodegib (25 μM or 50 μM) concentration dependently inhibits HCC and H1339 cells[3]. In Vivo: Vismodegib is a novel small molecule HPI, often used for clinical trials[1]. Vismodegib (0.3 to 75 mg/kg, p.o.) is highly efficacious in medulloblastoma allograft tumors. Vismodegib (> 46 mg/kg, p.o.) causes growth delay in patient-derived colorectal xenografts[4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Vismodegib
- Cat. No.:
- HY-10440
- Quantity:
Your information is safe with us.